Priority 3 from the Hidradenitis Suppurativa PSP

UNCERTAINTY: What is the impact of Hidradenitis Suppurativa and the treatments on people with Hidradenitis Suppurativa (physical, psychological, financial, social, quality of life)?  (JLA PSP Priority 3)
Overall ranking 3
JLA question ID 0017/3 
Explanatory note Not available for this PSP
Evidence

Protocol for Systematic Review: Ingram JR, Desai N, Kai AC, Chua SL, Woo P-N, Kerdel F, Burton T, Ormerod AD, Garner SE, Hood K, Piguet V. Interventions for hidradenitis suppurativa. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD010081. DOI: 10.1002/14651858.CD010081
 
Health Research Classification System category Skin
Extra information provided by this PSP
Comparison Diagnostic; Prognosis; Psychological therapy; Social care
Submitted by 63 patients, 32 clinicians
Outcomes to be measured Prognosis; management and or change of symptoms (pain, Hidradenitis Severity Score, time to remission and duration of remission, physician and patient assessment of change ); adverse effects* (morbidity, hospital admission), or complications (adverse effects leading to treatment discontinuation ,increased duration of treatment); acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life*; and health related costs.
 
*Signifies Primary outcomes
PSP information
PSP unique ID 0017
PSP name Hidradenitis Suppurativa
Total number of uncertainties identified by this PSP. 55  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 6 December 2013